Focused On-demand Library for Pre-mRNA-processing factor 17

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

O60508

UPID:

PRP17_HUMAN

Alternative names:

Cell division cycle 40 homolog; EH-binding protein 3; PRP17 homolog

Alternative UPACC:

O60508; B2RBC5; O75471; Q5SRN0; Q9UPG1

Background:

Pre-mRNA-processing factor 17, also known as Cell division cycle 40 homolog, EH-binding protein 3, and PRP17 homolog, plays a crucial role in pre-mRNA splicing as part of the activated spliceosome. Its involvement in embryonic brain development, independent of proline isomerization, underscores its significance in cellular processes.

Therapeutic significance:

The protein's link to Pontocerebellar hypoplasia 15, characterized by severe brain structural defects and impaired intellectual development, highlights its therapeutic potential. Understanding the role of Pre-mRNA-processing factor 17 could open doors to potential therapeutic strategies for this debilitating condition.